Search
Paliroden
go.drugbank.com/drugs/DB05454InvestigationalIt is indicated for use in Alzheimer's Disease and Parkinson’s.
GEM-231
go.drugbank.com/drugs/DB05798InvestigationalGEM231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1alpha regulatory subunit of cAMP dependent protein kinase. A monoclonal antibody combined with a toxic substance that is used treat certain types of acut...
Phloroglucinol
go.drugbank.com/drugs/DB12944InvestigationalPhloroglucinol has been used in trials studying the diagnostic of Colonoscopy.
Categories: Drugs for Functional Gastrointestinal Disorders, Compounds used in a research, industrial, or household settingPeldesine
go.drugbank.com/drugs/DB02568InvestigationalIt has undergone phase I trials for the treatment of Human Immunodeficiency Virus (HIV) infections.
Etaracizumab
go.drugbank.com/drugs/DB12213InvestigationalEtaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer.
Pipequaline
go.drugbank.com/drugs/DB13991ExperimentalPipequaline has a similar pharmacological profile to the reported for the benzodiazepines. … However, it presents a significant set of anxiolytic properties with a very little sedative, amnestic or anticonvulsant effect.
UDP-alpha-D-xylose
go.drugbank.com/drugs/DB01713ExperimentalThe decarboxylation product of UDPglucuronic acid, which is used for formation of the xylosides of seryl hydroxyl groups in mucoprotein synthesis. Also forms plant xylans.
TSHA-118
go.drugbank.com/drugs/DB16996ExperimentalTSHA-118 is a self-complementary AAV9 gene replacement therapy designed to express a human codon-optimized CLN1 transgene for the treatment of CLN1 disease.
Esuberaprost
go.drugbank.com/drugs/DB18464InvestigationalEsuberaprost (GP-1681), a drug intended for participants with pulmonary arterial hypertension, was under investigation in clinical trial NCT03657095 to evaluate its efficacy and safety.
Vibecotamab
go.drugbank.com/drugs/DB18872InvestigationalVibecotamab is under investigation in clinical trial NCT05285813 (A Phase II Study of Vibecotamab (Xmab14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure).